Bioprocess Validation Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Bioprocess Validation Market Trends & Drivers

Rising Usage of Bioreactors Is a Key Trend

• The rapid technological progress and growing usage of bioreactors enable the affordable and flexible production of medication.
• The usage of bioreactors for the manufacturing of vaccines, medicines, and other pharmaceutical components is burgeoning.
• Monoclonal antibodies for the treatment of rheumatoid arthritis, cancer, and many other diseases are manufactured with the help of bioreactors.
• In many areas of the healthcare industry, especially research, bioreactors are used for the conversion of in-vitro 2D culture models and suspensions to the 3D form and imitate the natural physiological state at the site.
• Furthermore, it produces quality products because the conditions are accurately maintained and the product is extracted only at the end of the process.
• The rising requirement for personalized medicine, the trend of outsourcing laboratory testing services, and continuous R&D to ensure drugs are of the desired quality fuel the demand for bioprocess validation services.
• The FDA's General Principles of Process Validation guidelines require the documentation of evidence at all stages of bioprocess validation studies, to ensure that the products created are of the intended product quality.
• The FDA and EMA’s regulations aim to verify all procedures and ensure that they all follow GMP regulations.
• The FDA has updated some rules for biopharmaceutical manufacturing devices, such as strict quality controls for improved and safer products.
• WuXi Biologics uses a single-use bioreactor to reduce protein production costs by 70% and increase yield by 20%.

Increasing Complexity of Biopharmaceutical Products Is a Key Driver

• The expanding usage of modern medicines, such as biologics and biosimilars, is driving the this market.
• As per studies, compared to 448.1 billion in 2023, biologic sales around the world could be worth USD 745.1 billion by 2030.
• These medicines are made from living cells and are larger and more complicated than the conventional small-molecule drugs, which makes the R&D process complex.
• Hence, biopharma companies, research institutions, and academic institutes use these services to document every stage of the manufacturing process.
• The FDA’s AMT program supports the making of medicines in new and traditional ways for maximum safety and efficacy.
• This creates a high demand for these services for testing, keeping detailed records, and following GMP principles.
• In September 2024, the Indian government approved funding of INR 9,197 crore for the Bio-RIDE scheme from 2021 to 2026, to support the biomanufacturing and research processes.

Bioprocess Validation Market Segmentation Analysis

Offering Analysis

The service category held the larger market share, of 60%, in 2024, due to the increasing risk of product adulteration and the presence of regulatory guidelines on testing. Individuals are also becoming increasingly concerned for the purity, safety, and quality of pharma products; therefore, they are now adopting only quality-certified bioproducts. The identification of the hazards posed by the leachables contained in packaging and closed processing systems has become essential in the drug discovery procedure, as a significant enough presence of leachables can lead to the premature perishing of bioproducts.

The product category will have the higher CAGR, of 11.3%, due to the rising usage of a variety of filters to ensure the efficacy and safety of biopharmaceutical products at every step of their production. In 2023, Pall Corporation launched its new advanced filters for viral vectors for gene therapy and CAR-T treatments. The FDA has revised its rules for the integrity of filter tests during biopharmaceutical manufacturing to minimize the contamination risks.

The offerings analyzed in this report are: 

• Product (Faster-Growing Category)
  • Filter elements
  • Media containers and bags
  • Freezing and thawing process bags
  • Mixing systems
  • Bioreactors
  • Transfer systems
• Service (Larger Category)
  • Extractables/Leachables testing services
  • Bioprocess residuals testing
  • Viral clearance testing
  • Filtration and fermentation systems testing

End User Analysis

The pharmaceutical & biotech companies category held the largest market share, of 65%, in 2024, due to the rising requirement for biopharma products and stringent regulatory standards implemented to ensure the quality and validity of the bioprocesses involved in biopharmaceutical production. The high cost of the materials used by biopharma companies for the development of various products for the treatment of individuals further encourages the development of the category.

The contract development & manufacturing organizations category will have the highest CAGR, of 11.4%, due to the rising demand for third-party services for validation and drug manufacturing. Studies predict that CDMOs could generate almost USD 32 billion by 2030 by providing services for biologic research, development, and production.

The end users analyzed in this report are: 

• Pharmaceutical Companies & Biotech Companies (Larger Category)
• Contract Development & Manufacturing Organizations (Faster-Growing Category)

Bioprocess Validation Market Regional Analysis

North America held the largest market share, of 40%, in 2024 due to the large number of key players and the strict government mandates to avail bioprocess validation services. Moreover, the presence of a huge number of outsourcing service providers in the region fuels the demand. In addition, Canada and the U.S. are spending increasingly on pharma/biopharma research and development to meet quality assurance. As per the European Federation of Pharmaceutical Industries and Associations, the U.S. spend EUR 71,459,000,000 on pharmaceutical R&D in 2022.

Asia-Pacific will have the highest CAGR, of 11.5%, due to the rising government support for pharmaceutical R&D, growing trend of outsourcing, and ballooning geriatric population. The United Nations says that almost a quarter of the APAC population will be over the age of 60 by 2050, by which time this population will be 1.3 billion.

Moreover, the investment in bio-manufacturing infrastructure in the region is high, which is responsible for the advancements in the validation processes. Essentially, the rising overall healthcare expenditure and the increasing funding in R&D setups by government agencies propel the demand for bioprocess validation services. Furthermore, the growing awareness of the advantages of vaccines and their use in preventing several acute infections drive governments to take initiatives for the development, implementation, and progress of these processes in the region.

The geographical breakdown of the market is as follows: 

• North America (Largest Regional Market)
  • U.S. (Largest and Fastest-Growing Category)
  • Canada
• Europe
  • Germany (Largest Category)
  • U.K. (Faster-Growing Category)
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • China (Largest Category)
  • India (Faster-Growing Category)
  • Japan
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil (Largest and Fastest-Growing Category)
  • Mexico
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Category)
  • South Africa
  • U.A.E. (Faster-Growing Category)
  • Rest of MEA

Bioprocess Validation Market Competitive Landscape

The market is fragmented due to several market players providing expert services according to customer needs. The increasing trend of outsourcing bioprocess validation and drug manufacturing to specialized third-party providers contributes to the market fragmentation. Moreover, the presence of key players in North America and Europe promotes competition and innovation, with no single player holding a major share.

Bioprocess Validation Market News

• In November 2024, Thermo Fisher Scientific Inc. signed an MoU with the Telangana government to develop a bioprocess design center in Genome Valley, Hyderabad. This 10,000 square-foot facility, scheduled to be operationalized in early 2025, has upstream and downstream, single-use scale-up manufacturing, cell-culture media development, and product validation capabilities. Equipped with single-use bioreactors, the center also provides infrastructure, research solutions, and technical expertise on a pay-per-use basis.
• In May 2024, Sartorius AG and Sanofi SA partnered to create the integrated and continuous biomanufacturing platform for downstream processing, to improve the quality and speed in pharma R&D.
• In February 2024, AbbVie Inc. and Tentarix Biotherapeutics collaborated to develop multi-specific, conditionally active biologics for cancers and autoimmune conditions.
• In November 2023, Aragen Life Sciences Ltd. announced plans to invest USD 30 million in a 160,000-square-meter facility in Bengaluru, which will house multiple manufacturing suites, process development labs, and quality control labs for microbiological analytical applications.
• In October 2023, Global Life Sciences Solutions USA LLC (Cytiva) inaugurated a 3,000-square-foot factory in Pune that will develop bioprocessing equipment, such as virus filtration, tangential flow, and inactivation systems.